Outcome of myeloma patients with COVID-19 on active lenalidomide-based therapy: Does lenalidomide protect from severe COVID-19?

Benzer Materyaller

• An Intriguing Case of Eosinophilia with FIP1L1/PDGFRA Rearrangement Who Presented as Thrombotic Thrombocytopenic Purpura
  Yazar:: Alshehri, Hassan, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Thrombotic thrombocytopenic purpura - analysis of clinical features, laboratory characteristics and therapeutic outcome of 24 patients treated at a Tertiary Care Center in Saudi Arabia
  Yazar:: Iqbal, Shahid, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Prolonged Survival of a Patient with Chronic Myeloid Leukemia in Accelerated Phase with Recurrent Isolated Central Nervous System Blast Crisis
  Yazar:: Bin Salman, Ahmed A., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Systemic Lupus Erythematosus Presenting as Hematoma of the Hand Due to Acquired Inhibitors to Factor VIII: Early and Prolonged Remission Achieved with Upfront Rituximab
  Yazar:: Zaidi, Abdul Rehman Z, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Aging and therapy‐related hypogammaglobulinemia causing pneumonia: An overlooked curable entity in the chaotic COVID‐19 pandemic
  Yazar:: Zaidi, Syed Ziauddin Ahmed, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)